Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 369 | 26 | 331 |
| Samples | 357 | 26 | 319 |
| Peptides | 247 | 23 | 223 |
Function
CCDC169-SOHLH2 · CCDC169-SOHLH2 readthrough
This locus represents naturally occurring read-through transcription between the neighboring C13orf38 (chromosome 13 open reading frame 38) and SOHLH2 (spermatogenesis and oogenesis specific basic helix-loop-helix 2) genes. The read-through transcript encodes a fusion protein that shares sequence identity with the products of each individual gene. [provided by RefSeq, Nov 2010].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000511166 | Q9NX45-3 | 369 | 247 |
Gene Properties
Recurrent Mutations
All 247 amino-acid changes on canonical ENST00000511166 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCDC169-SOHLH2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCDC169-SOHLH2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Endometrial Carcinoma | 0/42 0% | 18/612 3% |
| Gastric Carcinoma | 2/74 3% | 41/1809 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Colorectal Carcinoma | 5/143 4% | 67/3239 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Esophageal Carcinoma | 0/23 0% | 13/769 2% |
| Melanoma | 1/210 0% | 23/1899 1% |
| Hepatocellular Carcinoma | 1/46 2% | 23/2210 1% |
| Other Solid Cancers | 0/94 0% | 15/1515 1% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 13/1390 1% |
| Bladder Carcinoma | 1/58 2% | 8/956 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Neuroendocrine Tumour | 1/154 1% | 4/577 1% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 16/2550 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Breast Carcinoma | 1/144 1% | 12/3264 0% |
| Ovarian Carcinoma | 0/109 0% | 4/998 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Pancreatic Carcinoma | 0/89 0% | 6/1611 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Neuroblastoma | 1/87 1% | 3/1331 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
Mutation Distribution
Where CCDC169-SOHLH2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CCDC169-SOHLH2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 369 mutations in CCDC169-SOHLH2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|